99 related articles for article (PubMed ID: 28613403)
1. Opposite actions of urotensin II and relaxin-2 on cellular expression of fibronectin in renal fibrosis: A preliminary experimental study.
Cernaro V; Medici MA; Bianco F; Santoro D; Lacquaniti A; Romeo A; Lucisano S; Buemi A; Buemi M
Clin Exp Pharmacol Physiol; 2017 Oct; 44(10):1069-1071. PubMed ID: 28613403
[TBL] [Abstract][Full Text] [Related]
2. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
3. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo.
McDonald GA; Sarkar P; Rennke H; Unemori E; Kalluri R; Sukhatme VP
Am J Physiol Renal Physiol; 2003 Jul; 285(1):F59-67. PubMed ID: 12820641
[TBL] [Abstract][Full Text] [Related]
4. Role of urotensin II in advanced glycation end product-induced extracellular matrix synthesis in rat proximal tubular epithelial cells.
Tian L; Fu P; Zhou M; Gu Y; Li Y; Qi J
Int J Mol Med; 2016 Dec; 38(6):1831-1838. PubMed ID: 27840897
[TBL] [Abstract][Full Text] [Related]
5. Urotensin-II receptor antagonism does not improve renal haemodynamics or function in rats with endotoxin-induced acute kidney injury.
Nitescu N; Grimberg E; Guron G
Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1170-5. PubMed ID: 20880186
[TBL] [Abstract][Full Text] [Related]
6. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
7. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.
Heeg MH; Koziolek MJ; Vasko R; Schaefer L; Sharma K; Müller GA; Strutz F
Kidney Int; 2005 Jul; 68(1):96-109. PubMed ID: 15954899
[TBL] [Abstract][Full Text] [Related]
8. Urotensin II Induces ER Stress and EMT and Increase Extracellular Matrix Production in Renal Tubular Epithelial Cell in Early Diabetic Mice.
Pang XX; Bai Q; Wu F; Chen GJ; Zhang AH; Tang CS
Kidney Blood Press Res; 2016; 41(4):434-49. PubMed ID: 27467277
[TBL] [Abstract][Full Text] [Related]
9. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts.
Dai HY; Kang WQ; Wang X; Yu XJ; Li ZH; Tang MX; Xu DL; Li CW; Zhang Y; Ge ZM
Regul Pept; 2007 Apr; 140(1-2):88-93. PubMed ID: 17188370
[TBL] [Abstract][Full Text] [Related]
10. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
[TBL] [Abstract][Full Text] [Related]
11. Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs.
Soni H; Adebiyi A
J Endocrinol; 2013 Jun; 217(3):317-26. PubMed ID: 23554507
[TBL] [Abstract][Full Text] [Related]
12. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo.
Unemori EN; Pickford LB; Salles AL; Piercy CE; Grove BH; Erikson ME; Amento EP
J Clin Invest; 1996 Dec; 98(12):2739-45. PubMed ID: 8981919
[TBL] [Abstract][Full Text] [Related]
13. The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.
Cheriyan J; Burton TJ; Bradley TJ; Wallace SM; Mäki-Petäjä KM; Mackenzie IS; McEniery CM; Brown J; Wilkinson IB
Br J Clin Pharmacol; 2009 Oct; 68(4):518-23. PubMed ID: 19843055
[TBL] [Abstract][Full Text] [Related]
14. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
[TBL] [Abstract][Full Text] [Related]
15. Urotensin II and renal function in the rat.
Song W; Abdel-Razik AE; Lu W; Ao Z; Johns DG; Douglas SA; Balment RJ; Ashton N
Kidney Int; 2006 Apr; 69(8):1360-8. PubMed ID: 16531985
[TBL] [Abstract][Full Text] [Related]
16. Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK.
Chen YL; Loh SH; Chen JJ; Tsai CS
Eur J Pharmacol; 2012 Apr; 680(1-3):88-94. PubMed ID: 22329895
[TBL] [Abstract][Full Text] [Related]
17. Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice.
Yung S; Zhang Q; Chau MK; Chan TM
Autoimmunity; 2015; 48(7):471-87. PubMed ID: 26099989
[TBL] [Abstract][Full Text] [Related]
18. Relaxin abrogates renal interstitial fibrosis by regulating macrophage polarization via inhibition of Toll-like receptor 4 signaling.
Chen L; Sha ML; Li D; Zhu YP; Wang XJ; Jiang CY; Xia SJ; Shao Y
Oncotarget; 2017 Mar; 8(13):21044-21053. PubMed ID: 28416741
[TBL] [Abstract][Full Text] [Related]
19. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
[TBL] [Abstract][Full Text] [Related]
20. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-β1 and collagen synthesis.
Yung S; Ng CY; Ho SK; Cheung KF; Chan KW; Zhang Q; Chau MK; Chan TM
J Autoimmun; 2015 Apr; 58():111-22. PubMed ID: 25666976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
